News
VXRT
0.8599
-4.10%
-0.0368
Palo Alto Networks Shares Drop After Q3 Results, In-Line Guidance: The Details
Palo Alto Networks, Inc. Reported its third-quarter financial results after the bell Monday. Palo Alto Networks reported quarterly earnings of $ per share. The company beat the analyst consensus estimate of $ billion in sales for the quarter. The company expects full-year earnings of between $ and $.
Benzinga · 1d ago
Weekly Report: what happened at VXRT last week (0513-0517)?
Weekly Report · 1d ago
12 Health Care Stocks Moving In Tuesday's Pre-Market Session
Gainers CareCloud (NASDAQ:CCLDO) stock moved upwards by to $ during Tuesday's pre-market session. Syra Health shares increased by $ during the session. The company's market cap stands at $ million. Losers Scorpius Holdings (AMEX:SCPX) and Inotiv stock declined by $ during the same session.
Benzinga · 05/14 12:06
VXRT Stock Earnings: Vaxart Meets EPS, Beats Revenue for Q1 2024
Vaxart reported earnings per share of -14 cents for the first quarter of 2024. The company reported revenue of $ million. Vaxart met the analyst estimate for revenue of $800,000. The company also reported results for the fourth quarter of 2015.
Investorplace · 05/14 00:56
Vaxart Inc reports results for the quarter ended in March - Earnings Summary
Vaxart Inc reports results for the quarter ended in March. The company reported a quarterly adjusted loss of 14 cents per share. Revenue rose to $ million from a year ago; analysts expected $ thousand. The average analyst rating on the shares is "buy"
Reuters · 05/13 21:22
The title of the article could be "Vaxart Inc. Q1 2024 Financial Report: Balance Sheet, Income Statement, and Cash Flow Statement Analysis".
Press release · 05/13 21:07
Vaxart up 10% on quarterly revenue beat, eyes COVID oral vaccine trial start in Q2
Vaxart up 10% on quarterly revenue beat, eyes COVID oral vaccine trial start in Q2. Company could launch a phase 2 trial of its oral pill XBB COVID-19 vaccine candidate against an approved mRNA vaccine as early as this quarter. Vaxart reported Q1 results that beat on the top line.
Seeking Alpha · 05/13 21:01
12 Health Care Stocks Moving In Monday's After-Market Session
Gainers Aesthetic Medical Intl (NASDAQ:AIH) shares moved upwards by to $ during Monday's after-market session. The company's, Q1 earnings came out today. Harrow and Vaxart also moved upwards during the session.
Benzinga · 05/13 20:31
Vaxart Stock Climbs After Blockbuster Q1 Revenue
Vaxart, Inc. Reported its first-quarter financial results after the bell Monday. The company reported quarterly losses of 14 cents per share. Vaxart's quarterly sales clocked in at $ million, up from $675,000 from the same period last year. The vaccine company is preparing for a Phase 2b clinical study.
Benzinga · 05/13 20:29
Vaxart To Meet With FDA In Mid-2024 To Evaluate Clinical Data And Discuss Next Steps For Its Norovirus Program; Anticipates Cash Runway Into Late Q4 Of 2024
Vaxart expects to initiate a Phase 2b study evaluating its oral pill XBB COVID-19 vaccine against an approved mRNA vaccine comparator as early as the second quarter of 2024. Cash, cash equivalents and investments totaled $ million as of March 31, 2024. Company anticipates cash runway into late 2024.
Benzinga · 05/13 20:14
Vaxart GAAP EPS of -$0.14 in-line, revenue of $2.18M beats by $1.38M
Vaxart GAAP EPS of -$ in-line, revenue of $ beats by $ in the first quarter of 2024. The company is developing an oral pill vaccine candidate to treat norovirus in infants. Vaxart anticipates cash runway into late 2024.
Seeking Alpha · 05/13 20:03
VAXART INC: ANTICIPATES CASH RUNWAY INTO LATE Q4 OF 2024
Reuters · 05/13 20:01
*Vaxart 1Q Rev $2.18M >VXRT
Dow Jones · 05/13 20:01
*Vaxart 1Q Loss $24.4M >VXRT
Dow Jones · 05/13 20:01
*Vaxart 1Q Loss/Shr 14c >VXRT
Dow Jones · 05/13 20:01
Press Release: Vaxart Provides Business Update -2-
With strictly enforced federal, state, and foreign regulations; that Vaxart may not be able to obtain, maintain, and enforce necessary patent and other intellectual property protection; and other risks. The company does not assume any obligation to update any forward-looking statements. The company's quarterly and annual reports are filed with the SEC.
Dow Jones · 05/13 20:01
Stocks with more than 10% short interest - Finviz Screener
Seeking Alpha · 05/13 17:07
Options Volatility and Implied Earnings Moves Today, May 13, 2024
TipRanks · 05/13 11:05
Options Volatility and Implied Earnings Moves This Week, May 13 – May 16, 2024
TipRanks · 05/13 11:00
Weekly Report: what happened at VXRT last week (0506-0510)?
Weekly Report · 05/13 10:05
More
Webull provides a variety of real-time VXRT stock news. You can receive the latest news about Vaxart Inc through multiple platforms. This information may help you make smarter investment decisions.
About VXRT
Vaxart, Inc. is a clinical-stage biotechnology company that is primarily focused on the development of oral recombinant vaccines based on its Vector-Adjuvant-Antigen Standardized Technology (VAAST) proprietary oral vaccine platform. Its vaccines are designed to be administered using pills that can be stored and shipped without refrigeration and eliminate the risk of needle-stick injury. Its development programs include pill vaccines designed to protect against norovirus (cause for acute gastroenteritis), coronavirus, including SARS-CoV-2 (COVID-19)), and influenza. In addition, it has generated preclinical data for its therapeutic vaccine candidate targeting cervical cancer and dysplasia caused by human papillomavirus. The Company's platform technology employs a vector-based approach and consists of various components, such as a vector (adenovirus type 5 (Ad5); an antigen (Ad5 DNA); an adjuvant (Toll-like receptor 3 (TLR3)), and its proprietary enteric-coated tablet.